New anti-aging therapy takes first human step

A Boston biotech company has begun its human trial on a groundbreaking anti-aging treatment. The patient with an age-related eye disease received the world’s first cellular reprogramming injection.

The experimental therapy developed by Life Biosciences aims to make older cells behave like younger ones by altering the way genes are expressed. The company was co-founded by Harvard geneticist David Sinclair.

The trial participant has glaucoma and received the experimental drug, ER-100, in one eye. Researchers will monitor the person over the next six months to evaluate both the treatment’s safety and its ability to restore damaged tissue. 

ER-100 is the first cellular rejuvenation therapy of its kind to receive FDA clearance to enter human clinical trials. Fewer than 20 participants will be there in the initial US trial.

How the technology works
The treatment is based on the Nobel Prize-winning work of Japanese scientist Shinya Yamanaka, who discovered proteins capable of reprogramming adult cells into a younger state.

Scientists now hope to partially reset aging cells without changing their core identity, potentially improving the function of organs such as the eyes, muscles, liver, and brain.

The field has attracted major investment from technology and pharmaceutical leaders, including Amazon’s Jeff Bezos and OpenAI’s Sam Altman, as well as companies Eli Lilly and Merck.

Despite the excitement, experts urge caution. Animal studies have linked some forms of cellular reprogramming to cancer, prompting researchers to build extra safety measures into the trial.

Scientists believe the research could eventually transform the treatment of age-related diseases, but they stress that the technology remains in its early stages and would still require years of testing before becoming widely available.